特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病A - 疫学予測:2030年

Hemophilia A - Epidemiology - 2030

発行 DelveInsight Business Research LLP 商品コード 923586
出版日 ページ情報 英文 120 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.99円で換算しております。
血友病A - 疫学予測:2030年 Hemophilia A - Epidemiology - 2030
出版日: 2020年02月01日 ページ情報: 英文 120 Pages
概要

主要7ヶ国 (米国、ドイツ、スペイン、イタリア、フランス、英国、日本) の血友病Aの総患者数は、2017年に42,458人に達し、診断・治療された総患者数は38,212人でした。

当レポートでは、世界の血友病A治療薬市場について調査分析し、疾患の背景、疫学、主要7ヶ国の市場動向について、体系的な情報を提供しています。

目次

第1章 主な考察

第2章 エグゼクティブサマリー

第3章 血友病A:疾患の背景と概要

  • イントロダクション
    • 血友病Aの徴候と症状
    • 血友病Aの遺伝パターン
    • 血友病Aの分子病態
    • 血友病Aの病態生理
    • 血友病Aの危険因子
  • 血友病Aの診断
    • 診断の確立
    • 分子遺伝学的検査
    • スクリーニング検査
    • 凝固因子検査
    • 阻害剤試験

第4章 疫学と患者集団

  • 疫学の主な調査結果
  • 前提条件と根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国

第5章 米国の疫学

  • 診断された総有病率
  • 重症度固有の有病率
  • 阻害剤あり/なしの有病率

第6章 EU5ヶ国の国別疫学

  • ドイツの疫学
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学

第7章 日本の疫学

  • 診断された総有病率
  • 重症度固有の有病率
  • 阻害剤あり/なしの有病率

第8章 付録

第9章 DelveInsightの機能

第10章 免責条項

第11章 DelveInsightについて

図表

List of Tables

  • Table 1 Summary of Hemophilia A Epidemiology (2017-2030)
  • Table 2 Summary of sources explored for the epidemiology of Hemophilia A
  • Table 3 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017-2030)
  • Table 4 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017-2030)
  • Table 5 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017-2030)
  • Table 6 Total Diagnosed Prevalence of Hemophilia A in the United States (2017-2030)
  • Table 7 Severity- Specific Prevalence of Hemophilia A in the US (2017-2030)
  • Table 8 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States (2017-2030)
  • Table 9 Total Diagnosed Prevalence of Hemophilia A in Germany (2017-2030)
  • Table 10 Severity- Specific Prevalence of Hemophilia A in Germany (2017-2030)
  • Table 11 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017-2030)
  • Table 12 Total Diagnosed Prevalence of Hemophilia A in France (2017-2030)
  • Table 13 Severity- Specific Prevalence of Hemophilia A in France (2017-2030)
  • Table 14 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017-2030)
  • Table 15 Total Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Table 16 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Table 17 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017-2030)
  • Table 18 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017-2030)
  • Table 19 Severity-Specific Prevalence of Hemophilia A in Spain (2017-2030)
  • Table 20 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017-2030)
  • Table 21 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Table 22 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Table 23 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017-2030)
  • Table 24 Total Diagnosed Prevalence of Hemophilia A in Japan (2017-2030)
  • Table 25 Severity- Specific Prevalence of Hemophilia A in Japan (2017-2030)
  • Table 26 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017-2030)

List of Figures

  • Figure 1 Coagulation Cascade and the Effects of Recombinant Activated Factor Vll (rFVlla)
  • Figure 2 Inheritance Pattern of Hemophilia A
  • Figure 3 Established and Proposed Risk Factors for Inhibitor Development
  • Figure 4 Screening Tests for Hemophilia A
  • Figure 5 Total Diagnosed Prevalence of HemophiliaA in the 7MM (2017-2030)
  • Figure 6 Severity- Specific Prevalence of Hemophilia A in the 7MM (2017-2030)
  • Figure 7 Prevalence of Hemophilia A with or without Inhibitors the 7MM (2017-2030)
  • Figure 8 Total Diagnosed Prevalence of Hemophilia A in the United States (2017-2030)
  • Figure 9 Severity- Specific Prevalence of Hemophilia A in the US (2017-2030)
  • Figure 10 Prevalence of Hemophilia A with Inhibitors & Without Inhibitors in the United States (2017-2030)
  • Figure 11 Total Diagnosed Prevalence of Hemophilia A in Germany (2017-2030)
  • Figure 12 Severity- Specific Prevalence of Hemophilia A in Germany (2017-2030)
  • Figure 13 Prevalence of Hemophilia A with or Non-Inhibitors in Germany (2017-2030)
  • Figure 14 Total Diagnosed Prevalence of Hemophilia A in France (2017-2030)
  • Figure 15 Severity- Specific Prevalence of Hemophilia A in France (2017-2030)
  • Figure 16 Prevalence of Hemophilia A with or Non-Inhibitors in France (2017-2030)
  • Figure 17 Total Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Figure 18 Severity-Specific Diagnosed Prevalence of Hemophilia A in Italy (2017-2030)
  • Figure 19 Prevalence of Hemophilia A with or Non-Inhibitors in Italy (2017-2030)
  • Figure 20 Total Diagnosed Prevalence of Hemophilia A in the Spain (2017-2030)
  • Figure 21 Severity-Specific Prevalence of Hemophilia A in Spain (2017-2030)
  • Figure 22 Prevalence of Hemophilia A with or Non-Inhibitors in Spain (2017-2030)
  • Figure 23 Total Diagnosed Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Figure 24 Severity-Specific Prevalence of Hemophilia A in the United Kingdom (2017-2030)
  • Figure 25 Prevalence of Hemophilia A with or Non-Inhibitors in the United Kingdom (2017-2030)
  • Figure 26 Total Diagnosed Prevalence of Hemophilia A in Japan (2017-2030)
  • Figure 27 Severity- Specific Prevalence of Hemophilia A in Japan (2017-2030)
  • Figure 28 Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan (2017-2030)
目次
Product Code: DIEI0617

DelveInsight's Hemophilia A- Epidemiology-2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Hemophilia A in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Hemophilia A - Disease Understanding and Treatment Algorithm

Hemophilia A is an X chromosome-linked genetic disorder caused by the mutations in the genes for factor VIII (FVIII). This clotting factor is a part of the intrinsic pathway of blood coagulation. Without enough factor VIII, the blood cannot clot properly to control bleeding. It is mainly a defect in the gene on chromosome X, females have two copies of the X chromosome. So, if the factor VIII gene on one chromosome does not work, the gene on the other chromosome can do the job of making enough factor VIII. On the other hand, males have only one X chromosome; if the factor VIII gene is missing on the male X chromosome, he will have hemophilia A that is why the most people with Hemophilia A are male.

The symptoms of Hemophilia A can vary greatly from one person to another, it ranges from mild to moderate to severe. The age of onset and frequency of bleeding episodes depend upon the amount of factor VIII protein and overall clotting ability of the blood. In most individuals, regardless of severity, bleeding episodes tend to be more frequent in childhood and adolescence than in adulthood.

Additionally, the diagnosis of Hemophilia A depends on the identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation, and a variety of specialized laboratory tests. The identification of a hemizygous F8 pathogenic variant on molecular genetic testing in a male proband confirms the diagnosis.

The treatment of Hemophilia A is mainly focused on the prophylaxis as there is no cure for hemophilia A. Treatment consists of replacing the missing clotting protein (factor VIII) and preventing the complications associated with the disorder. Replacement of this protein may be obtained through recombinant factor VIII, which is artificially created in a lab. Several recombinant forms of factor VII are also approved for the treatment of hemophilia A. In some cases, subjects with hemophilia A may develop 'inhibitors' against the replacement factor VIII. Inhibitors are antibodies, which are specialized proteins created by the body's immune system to combat foreign or invading substances such as toxins or bacteria. The immune system may recognize replacement factor VIII as 'foreign' and create these antibodies (inhibitors), which target and destroy the replacement factor. For inhibitors treatment is mainly dependent on bypassing agents and immne tolerance therapy (ITI).

Hemophilia A-Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors] scenario of Hemophilia A in the 7MM Countries covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

DelveInsight's analysts have assessed that the total prevalent population of Hemophilia A in the 7MM was 42,458 in 2017. In addition to this, it was accessed that the total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.

DelveInsight's estimate suggests that the United States witnessed the highest number of cases with Hemophilia A, as compared to other 7MM countries. As per DelveInsight's estimates, the country accounted for approximately 14,200 cases in 2017. Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy. On the other hand, the Spain had the lowest prevalent population of Hemophilia A in 2017. Furthermore, Japan had 5,297 prevalent cases for Hemophilia A in 2017.

It was also observed that Severe Hemophilia A cases are more prominent in comparison to Mild and Moderate. In the United States, observed number of mild cases were 3,195, i.e., 25% of the diagnosed and Treated Hemophilia A patient pool in 2017. Additionally, moderate and severe accounts for 75% of the Hemophilia A patient pool. Among the Hemophilia A patients, i.e., with or without/Non-Inhibitors, the latter one accounts for a higher number of Hemophilia A cases.

Report Scope

  • The report covers a detailed overview of Hemophilia A explaining its causes, symptoms, classification, and pathophysiology.
  • The report provides insight about the historical and forecasted patient pool for seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM countries with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology by Total Prevalence of Hemophilia A, Diagnosed and Treated Prevalent Population of Hemophilia A, Severity-Specific Prevalence of Hemophilia A, and Prevalence of Hemophilia A with Inhibitors and Without Inhibitors.

Hemophilia A Report Key Strengths

  • 11-Year Forecast
  • 7MM Coverage
  • Total Prevalence of Hemophilia A
  • Diagnosed and Treated Prevalent Population of Hemophilia A
  • Severity-Specific Prevalence of Hemophilia A
  • Prevalence of Hemophilia A with Inhibitors and without Inhibitors

Hemophilia A Report Assessment

  • Patient segmentation
  • Disease risk and burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary

3. Hemophilia A: Disease Background and Overview

  • 3.1. Introduction
    • 3.1.1. Sign and Symptoms of Hemophilia A
    • 3.1.2. Inheritance Pattern of Hemophilia A
    • 3.1.3. Molecular Pathogenesis of Hemophilia A
    • 3.1.4. Pathophysiology of Hemophilia A
    • 3.1.5. Risk Factors of Hemophilia A
  • 3.2. Diagnosis of Hemophilia A
    • 3.2.1. Establishing the Diagnosis
    • 3.2.2. Molecular Genetic Testing
    • 3.2.3. Screening Tests
    • 3.2.4. Clotting Factor Tests
    • 3.2.5. Inhibitor Testing

4. Epidemiology and Patient Population

  • 4.1. Epidemiology Key Findings
  • 4.2. Assumptions and Rationale: 7MM
  • 4.3. Epidemiology Scenario: 7MM
    • 4.3.1. Total Diagnosed Prevalence of Hemophilia A in the 7MM
    • 4.3.2. Severity- Specific Prevalence of Hemophilia A in the 7MM
    • 4.3.3. Prevalence of Hemophilia A with or without Inhibitors the 7MM

5. United States Epidemiology

  • 5.1. Total Diagnosed Prevalence of Hemophilia A in the United States
  • 5.2. Severity- Specific Prevalence of Hemophilia A in the United States
  • 5.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in the United States

6. EU-5 Country-wise Epidemiology

  • 6.1. Germany Epidemiology
    • 6.1.1. Total Diagnosed Prevalence of Hemophilia A in Germany
    • 6.1.2. Severity- Specific Prevalence of Hemophilia A in Germany
    • 6.1.3. Prevalence of Hemophilia A with or without Inhibitors in Germany
  • 6.2. France Epidemiology
    • 6.2.1. Total Diagnosed Prevalence of Hemophilia A in France
    • 6.2.2. Severity- Specific Prevalence of Hemophilia A in France
    • 6.2.3. Prevalence of Hemophilia A with or without Inhibitors in France
  • 6.3. Italy Epidemiology
    • 6.3.1. Total Diagnosed Prevalence of Hemophilia A and B in Italy
    • 6.3.2. Severity-Specific Prevalence of Hemophilia A in Italy
    • 6.3.3. Prevalence of Hemophilia A with or without Inhibitors in Italy
  • 6.4. Spain Epidemiology
    • 6.4.1. Total Diagnosed Prevalence of Hemophilia A in Spain
    • 6.4.2. Severity- Specific Prevalence of Hemophilia A in Spain
    • 6.4.3. Prevalence of Hemophilia A with Inhibitors or Without-Inhibitors in Spain
  • 6.5. United Kingdom Epidemiology
    • 6.5.1. Total Diagnosed Prevalence of Hemophilia A in the United Kingdom
    • 6.5.2. Severity- Specific Prevalence of Hemophilia A in the United Kingdom
    • 6.5.3. Prevalence of Hemophilia A with Inhibitors or Non-Inhibitors in the United Kingdom

7. Japan Epidemiology

  • 7.1. Total Diagnosed Prevalence of Hemophilia A in Japan
  • 7.2. Severity- Specific Prevalence of Hemophilia A in Japan
  • 7.3. Prevalence of Hemophilia A with Inhibitors and Without Inhibitors in Japan

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight